Asenapine-containing adhesive patch

    公开(公告)号:US11850311B2

    公开(公告)日:2023-12-26

    申请号:US17281621

    申请日:2019-09-25

    CPC classification number: A61K9/7069 A61K31/407

    Abstract: An object of the present invention is to provide an asenapine-containing patch having excellent adhesiveness and handleability, which can persistently provide sufficient medicinal effects by suppressing cold flow during storage or application while enhancing skin permeability using a silicone-based pressure-sensitive adhesive base, and thereby maintaining the stability of the drug in the patch during storage, and maintaining an appropriate administration form for a long period of time. The present invention relates to a patch having a support and a pressure-sensitive adhesive layer, wherein the pressure-sensitive adhesive layer comprises asenapine and a silicone-based pressure-sensitive adhesive base, and the loss tangent (tan δ) of the pressure-sensitive adhesive layer is 0.75 to 1.5 at 1.0 Hz.

    ASENAPINE-CONTAINING ADHESIVE PATCH

    公开(公告)号:US20210369637A1

    公开(公告)日:2021-12-02

    申请号:US17281621

    申请日:2019-09-25

    Abstract: An object of the present invention is to provide an asenapine-containing patch having excellent adhesiveness and handleability, which can persistently provide sufficient medicinal effects by suppressing cold flow during storage or application while enhancing skin permeability using a silicone-based pressure-sensitive adhesive base, and thereby maintaining the stability of the drug in the patch during storage, and maintaining an appropriate administration form for a long period of time. The present invention relates to a patch having a support and a pressure-sensitive adhesive layer, wherein the pressure-sensitive adhesive layer comprises asenapine and a silicone-based pressure-sensitive adhesive base, and the loss tangent (tan δ) of the pressure-sensitive adhesive layer is 0.75 to 1.5 at 1.0 Hz.

    ROPINIROLE-CONTAINING PATCH AND PACKAGE THEREOF
    4.
    发明申请
    ROPINIROLE-CONTAINING PATCH AND PACKAGE THEREOF 有权
    ROPINIROLE包含PATCH及其包装

    公开(公告)号:US20140170205A1

    公开(公告)日:2014-06-19

    申请号:US14123148

    申请日:2012-05-23

    CPC classification number: A61K9/7053 A61K31/4045

    Abstract: A ropinirole-containing patch comprises an adhesive agent layer and a support layer, the adhesive agent layer containing ropinirole and/or a pharmaceutically acceptable salt thereof, wherein a content of the ropinirole and/or the pharmaceutically acceptable salt thereof in terms of free ropinirole in the adhesive agent layer satisfies the following two conditions: 5 to 13.2% by mass relative to a total mass of the adhesive agent layer, and 0.12 to 2.7 mg/cm2 per unit area of the adhesive agent layer.

    Abstract translation: 含罗匹尼罗的贴剂包含粘合剂层和支持层,所述粘合剂层含有罗匹尼罗和/或其药学上可接受的盐,其中根据游离罗哌卡罗的罗匹尼罗和/或其药学上可接受的盐的含量 粘合剂层满足以下两个条件:相对于粘合剂层的总质量为5〜13.2质量%,粘合剂层的每单位面积为0.12〜2.7mg / cm 2。

    Rotigotine-containing patch
    5.
    发明授权

    公开(公告)号:US11607394B2

    公开(公告)日:2023-03-21

    申请号:US16954627

    申请日:2018-12-14

    Abstract: The present invention provides a rotigotine-containing patch comprising: a backing layer; and an adhesive agent layer, wherein the adhesive agent layer contains rotigotine and/or a pharmaceutically acceptable salt thereof,
    the adhesive agent layer further contains a styrene-based thermoplastic elastomer, a petroleum-based resin and/or a terpene-based resin, an aliphatic alcohol, and a cross-linked polyvinylpyrrolidone, and
    in the adhesive agent layer, a mass ratio of a content of the rotigotine and/or the pharmaceutically acceptable salt thereof in terms of rotigotine free form and a content of the cross-linked polyvinylpyrrolidone (content of the rotigotine and/or the pharmaceutically acceptable salt thereof in terms of rotigotine free form:content of the cross-linked polyvinylpyrrolidone) is 10:3 to 1:3.

    PATCH
    6.
    发明申请
    PATCH 有权
    补丁

    公开(公告)号:US20150250877A1

    公开(公告)日:2015-09-10

    申请号:US14433939

    申请日:2013-10-08

    Abstract: A patch comprising a support layer and an adhesive agent layer, wherein the adhesive agent layer comprises at least one drug selected from the group consisting of emedastine and pharmaceutically acceptable salts thereof, at least one adhesive agent selected from the group consisting of rubber-based adhesive agents and silicone-based adhesive agents, and an alkali metal fumarate as a cohesive force-improving agent for the adhesive agent layer.

    Abstract translation: 一种贴剂,其包括支持层和粘合剂层,其中所述粘合剂层包含至少一种选自依达克汀及其药学上可接受的盐的药物,至少一种选自橡胶基粘合剂 助剂和硅氧烷粘合剂,以及作为粘合剂层的内聚力改善剂的富马酸碱金属盐。

    Asenapine-containing adhesive patch

    公开(公告)号:US11590106B2

    公开(公告)日:2023-02-28

    申请号:US17281623

    申请日:2019-09-25

    Abstract: An object of the present invention is to provide an asenapine-containing patch having excellent sustained-release properties while enhancing skin permeability by using a silicone-based pressure-sensitive adhesive base. The present invention relates to a patch having a support and a pressure-sensitive adhesive layer, wherein the pressure-sensitive adhesive layer comprises asenapine and/or a pharmaceutically acceptable salt thereof, a silicone-based pressure-sensitive adhesive base and a release control agent, and the ratio of the maximum skin permeation rate of asenapine to the minimum skin permeation rate from the time when the maximum skin permeation rate is reached to 24 hours is less than 1.62.

    ASENAPINE-CONTAINING ADHESIVE PATCH

    公开(公告)号:US20210393587A1

    公开(公告)日:2021-12-23

    申请号:US17281623

    申请日:2019-09-25

    Abstract: An object of the present invention is to provide an asenapine-containing patch having excellent sustained-release properties while enhancing skin permeability by using a silicone-based pressure-sensitive adhesive base. The present invention relates to a patch having a support and a pressure-sensitive adhesive layer, wherein the pressure-sensitive adhesive layer comprises asenapine and/or a pharmaceutically acceptable salt thereof, a silicone-based pressure-sensitive adhesive base and a release control agent, and the ratio of the maximum skin permeation rate of asenapine to the minimum skin permeation rate from the time when the maximum skin permeation rate is reached to 24 hours is less than 1.62.

Patent Agency Ranking